The new generation of liquid intravenous immunoglobulin formulations in patient care: A comparison of intravenous immunoglobulins

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 176-184

  Stein, Mark R ^a  

^a Allergy Associates of the Palm Beaches   (United States)

Author keywords

Intravenous immunoglobulin; Liquid IGIV formulation; Physicochemical properties; Stability; Tolerability

Indexed keywords

ANTIHISTAMINIC AGENT; CARIMUNE NF; CORTICOSTEROID; EXCIPIENT; GAMMAGARD SD; GAMMAPLEX; GLUCOSE; GLYCINE; HUMAN IMMUNOGLOBULIN; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULINE IV; LIQUID INTRAVENOUS IMMUNOGLOBULIN; MALTOSE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROLINE; SODIUM; SODIUM CHLORIDE; SORBITOL; STABILIZING AGENT; STERILE WATER; SUGAR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BACKACHE; BONE MARROW TRANSPLANTATION; CHILL; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FLUSHING; FREEZE DRYING; HEADACHE; HEALTH CARE PERSONNEL; HEART FAILURE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPEROSMOLARITY; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFUSION; KIDNEY FAILURE; LIQUID; LOADING DRUG DOSE; LUNG EMBOLISM; MALAISE; MIGRAINE; MYALGIA; NAUSEA; ORGAN TRANSPLANTATION; OSMOLALITY; PATIENT; PH; PRURITUS; SHIVERING; SIDE EFFECT; STROKE; SUBSTITUTION THERAPY; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; URTICARIA; VOMITING; WHEEZING; CHEMISTRY; DOSE RESPONSE; DRUG STABILITY; OSMOLARITY; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; OSMOLAR CONCENTRATION;

EID: 78049515693     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2214     Document Type: Article

References (82)

1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722-728.
2. Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians. 1953;66:200-202.
3. Gitlin D, Janeway CA. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol. 1956;1:318-329.
4. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1-7.
5. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101(4):435-439.
6. Orange JS, Hossny EM, Weiler CR, et al; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immune globulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117;(4 suppl 1):S525-S553.
7. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol. 2009;66(5):597-603.
8. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1-11.
9. Bonilla FA, Bernstein IL, Khan DA, et al; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94:S1-S63.
10. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfusion Med Rev. 2010;24(suppl 1):S28-S50.
11. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3:653-664.
12. Yamani MH, Avery R, Mawhorter S, et al. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transplant Infect Dis. 2001;3(suppl 2):40-43.
13. Stucki M, Boschetti N, Schaefer W, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals. 2008;36(4):239-247.
14. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98(11):12-28.
15. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):595-599.
16. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005;62(suppl 3):S5-S11.
17. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3):206-218.
18. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25(11 pt 2):78S-84S.
19. Gammagard SD [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2008.
20. Carimune NF [package insert]. King of Prussia, PA: CSL Behring LLC; 2005.
21. Gaines A, Varricchio F, Kapit R, et al. Renal insufficiency and failure associated with globulin intravenous therapy. Morb Mortal Wkly Rep. 1999;48:518-521.
22. Flebogamma 5% DIF [package insert]. Los Angeles, CA: Grifols Biologicals, Inc; 2006.
23. Octagam [package insert]. Centreville, VA: Octapharma USA, Inc; 2006.
24. Gammaplex [package insert]. Elstree, UK: Bio Products Laboratory; 2009.
25. Gamunex [package insert]. Research Triangle Park, NC: Talecris. Biotherapeutics, Inc; 2008.
26. Privigen [package insert]. King of Prussia, PA: CSL Behring LLC; 2010.
27. Gammagard Liquid [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2005.
28. Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. EJHP Practice. 2007;2:66-68.
29. Sorensen R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm. 2007;13(3):278-283.
30. Berger M; the Flebogamma® 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma®. J Clin Immunol. 2007;27(6):628-633.
31. Cramer M, Frei R, Sebald A, et al. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen©) stabilized with L-proline. Vox Sang. 2009;96(3):219-225.
32. Kallenberg CG. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin Exp Immunol. 2007;150(3):437-441.
33. Ballow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang. 2003;84(3):202-210.
34. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003;3(9):1325-1333.
35. Church JA, Leibl H, Stein MR, et al; US-PID-IGIV 10%-Study Group10. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26(4):388-395.
36. Björkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo-or agammaglobulinemia. Vox Sang. 2006;90(4):286-293.
37. Stein MR, Nelson RP, Church JA, et al; for the IgPro10 in PID Study Group. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. Clin Immunol. 2009;29(1):137-144.
38. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol. 2006;6(4):523-527.
39. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: detection of IgE antibodies to IgA. N Engl J Med. 1986;314(9):560-564.
40. Manlhiot C, Tyrrell PN, Liang L, et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008;121(3): e626-e630.
41. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet. 1992;339(8794):682-684.
42. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60(11):1822-1824.
43. Bolli R, Woodtli K, Bartschi M, et al. L-proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38(1):150-157.
44. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am. 2008;28:779-802.
45. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol. 1997;20:385-393.
46. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003;50(3):172-175.
47. Berger M, Cunningham-Rundles C, Bonilla FA, et al. Carimune NF is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol. 2007;27(5):503-509.
48. Brennan VM, Salomé-Bentley NJ, Chapel HM; Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133(2):247-251.
49. Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136(1):111-113.
50. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173-184.
51. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6(4):535-542.
52. Gelfand EW, Hanna K; and the IGIV-C Increased Maximum Infusion Rate Study Group. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol. 2006;26(3):284-290.
53. Sleasman JW, Duff CM, Dunaway T, et al. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen®, at different infusion rates. J Clin Immunol. 2010;30(3):442-448.
54. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev. 2003;17(4):241-251.
55. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38(12):2059-2067.
56. Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J Nephrol. 1998;11(3):157-161.
57. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007;122(2):156-162.
58. Björkander J, Hammarstrom L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 1987;7(1):8-15.
59. Koskinen S, Tolo H, Hirvonen M, Koistinen J. Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults. J Clin Immunol. 1995;15(4):194-198.
60. Aghamohammadi A, Cheraghi T, Gharagozlou M, et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. 2009;29(1):130-136.
61. Eijkhout HW, van den Broek PJ, van der Meer JWM. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med. 2003;61(6):213-217.
62. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement by slow subcutaneous infusion. Ann Intern Med. 1980;98(1):55-56.
63. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121(4):259-262.
64. Iagaru N, Cinteza E, Cochino AV. Adverse reactions to intravenous immunoglobulin therapy. Medica. 2007;2:294-299.
65. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica. 1993;78(6 suppl 2):35-40.
66. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48(8):1598-1601.
67. Marie I, Maurey G, Hervé F, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714-721.
68. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313-318.
69. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44(2):223-226.
70. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30-34.
71. Cailleux N, Levesque H, Bastit D, et al. A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome) [in French]. Rev Med Interne. 1998;19(6):434-437.
72. Gajic O, Moore SB. Transfusion-related acute lung injury. Mayo Clin Proc. 2005;80(6):766-770.
73. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion. 2001;41(2):264-268.
74. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28(2):413-437.
75. Asia Pacific Immunoglobulins in Immunology Expert Group. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency. November 2008.
76. Desai SH, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124(4):854-856.
77. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008;28(4):737-764.
78. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1(8541):1075-1077.
79. Gelfand EW, Reid B, Roifman CM. Intravenous immune serum globulin replacement in hypogammaglobulinemia. A comparison of high-versus low-dose therapy. Monogr Allergy. 1988;23:177-186.
80. Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J. 1988;7(5 suppl):S92-S96.
81. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al; Inter-University Working Party for the Study of Immune Deficiencies. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135(3):165-174.
82. Roifman CM, Berger M, Notarangelo LD. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin North Am. 2008;28(4):875-876.